Document text
Principal Investigator: Karen L. Kotloff
Organization: UNIVERSITY OF MARYLAND BALTIMORE
Fiscal Year: 2021
Award: $1,121,472
Funding agency: National Institute of Allergy and Infectious Diseases
Summary/Abstract
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), causative agent of the coronavirus
disease of 2019 (COVID-19) which was designated as a pandemic respiratory illness (WHO - 2020), has
infected over 172 million people worldwide and resulted in over 3.7 million deaths, including > 596,000 in the
United States (June 3, 2021, WHO; www.who.int). Multiple Phase 3 efficacy trials of SARS-CoV-2 vaccine
constructs are underway or in long-term follow-up in the U.S, and these studies have supported 3 Emergency
Use Authorizations (EUAs) for COVID vaccines. However, logistical and manufacturing obstacles are limiting
the number of vaccines available at any one time. Further, the emergence of variant strains has raised
concerns about the breadth of immunity and protection achieved by the current vaccines. WHO SAGE and
CDC ACIP have identified the safety and immunogenicity of mixed schedules as a critical and immediate
research priority to inform policy on the use of mixed schedules.
Knowledge of the safety, tolerability, and immunogenicity of a delayed boost vaccine incorporating a
heterologous platform or variant spike lineage administered following EUA prime dosing regimens may
greatly stretch the ability to immunize against SARS-CoV-2 at a population level, induce immunity to variant
circulating strains and improve upon the breadth and durability of protection. The heterologous boost strategy
will also provide an opportunity to thoroughly evaluate innate, cellular, and humoral immune responses
elicited from the multiple prime boost combinations using very similar immunogens, utilizing mRNA,
adenovirus- vectored, and protein- based platforms. As new immunogens are manufactured to closely match
emerging variants, these foundational data will be key to the evaluation of future variant and heterologous
prime- boost strategies. This phase 1/2 clinical trial will evaluate the safety and immunogenicity of different
heterologous delayed doses (boosts) in those who received an EUA vaccine (either prior to participation in
this trial, or as part of this trial).
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Ad vector><Adenoviral Vector><Adenovirus Vector><Adverse Experience><Adverse event><Antigens><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><CDC><COVID><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 vaccine><COVID19 virus><CV-19><CV19><Centers for Disease Control><Centers for Disease Control and Prevention><Centers for Disease Control and Prevention (U.S.)><Cessation of life><CoV disease><CoV-2><CoV2><Data><Death><Dose><Evaluation><FDA EUA><FDA Emergency Use Authorization><Food and Drug Administration EUA><Food and Drug Administration Emergency Use Authorization><Foundations><Future><Immune response><Immunity><Immunize><Immunological response><Knowledge><Length of Life><Logistics><Long-term Follow-up><Longevity><Longterm Follow-up><Messenger RNA><Persons><Phase><Phase 1/2 Clinical Trial><Phase I/II Clinical Trial><Policies><Population><Proteins><Public Health><Regimen><Research Design><Research Priority><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Sampling><Schedule><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Stretching><Study Type><T cell response><Time><United States><United States Centers for Disease Control><United States Centers for Disease Control and Prevention><Vaccinated><Vaccination><Vaccines><Variant><Variation><Wuhan coronavirus><access to vaccination><access to vaccines><adeno vector><adenovector><base><booster vaccine><clinical research site><clinical site><cohort><corona virus disease><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><deliver vaccines><efficacy trial><emergency use authorization><hCoV19><host response><immune system response><immunogen><immunogenicity><immunoresponse><improved><life span><lifespan><long-term followup><longterm followup><mRNA><nCoV2><new vaccines><next generation vaccines><novel vaccines><pandemic><pandemic disease><phase 1 designs><phase I designs><prospective><respiratory><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><study design><vaccination access><vaccination availability><vaccine access><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine availability><vaccine delivery><vaccine for novel coronavirus>